Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $2.80.
Several equities analysts have recently weighed in on the company. Ladenburg Thalmann & Co. Inc. began coverage on Aprea Therapeutics in a report on Wednesday, October 14th. They issued a “buy” rating and a $2.00 price objective for the company. Wedbush lowered their target price on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Thursday, October 15th.
Read Our Latest Analysis on Aprea Therapeutics
Aprea Therapeutics Price Performance
Shares of APRE traded down $0.02 during midday trading on Friday, hitting $0.42. The stock had a trading volume of 91,407 shares, compared to its average volume of 156,240. The company has a 50 day simple moving average of $0.63 and a two-hundred day simple moving average of $0.73. Aprea Therapeutics has a twelve month low of $0.41 and a twelve month high of $1.49. The firm has a market cap of $5.91 million, a price-to-earnings ratio of -0.59 and a beta of 1.74.
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Analysts forecast that Aprea Therapeutics will post -0.39 EPS for the current fiscal year.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc. (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its research is centered on small-molecule treatments intended to address molecular abnormalities that contribute to tumor growth and resistance to treatment. The company’s lead historical program was eprenetapopt, also known as APR-246, an investigational therapy designed to reactivate mutant p53, a tumor-suppressor protein frequently altered in cancer. Eprenetapopt was studied in hematologic malignancies, including TP53-mutant myelodysplastic syndromes and acute myeloid leukemia.
Featured Stories
- Five stocks we like better than Aprea Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
